Report

IntroductionMeans-tested benefits are designed to support basic needs such as food, health insurance, and child care for households with low incomes. When considering whether to take a new job opportunity that will increase their income, recipients of these benefits may be forced to consider trade-offs. For example:

This second report focuses largely on updating pre-NSA trends in claims data presented in the first report.

This report outlines a feasibility study focused on obtaining identifiers for self-directed Home and Community-Based Services (HCBS) users within Medicaid claims data. Financial Management Services (FMS) entities assist individuals in managing the financial aspects of self-directed care, including payroll and billing.

This research report describes patterns in insurance coverage and uninsurance rates in rural and urban areas, reviews non-financial challenges in accessing care faced by many rural residents, and describes disparities in health outcomes between urban and rural areas.

The final summary report on “Developing and Piloting a Federal Evaluation Approach for Complex Cross-Agency Initiatives: The Overdose Prevention Test Case” lays out the findings of HHS effort to test a cross-departmental methodology.

This report outlines the major issues faced by the U.S. health care workforce. It addresses medical, dental and behavioral health components of the workforce as well as direct care workers. The report also describes opportunities for progress to address these issues and existing activities supported by the Department to address these issues.

This guidance, originally published in 2003, contains the following introduction:

The purpose of this research was to understand the relationship between state Medicaid payment rates to nursing homes and those facilities’ costs of providing care to Medicaid residents.

It is anticipated that extreme weather events due to climate change will increase the prevalence of a number of acute and chronic diseases. As a result, the demand for drugs to prevent or treat those conditions is likely to increase.

The cost of bringing a medical product to the U.S. market has been increasing and clinical trials constitute a large portion of these costs. In drug development, the clinical phase lasts an average of around 95 months compared to 31 months for the non-clinical phase and accounts for 69 percent of overall R&D costs (DiMasi, et al., 2016).